These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 23371395

  • 1. Observational study of once-daily insulin detemir in people with type 2 diabetes aged 75 years or older: a sub-analysis of data from the Study of Once daily LeVEmir (SOLVE).
    Karnieli E, Baeres FM, Dzida G, Ji Q, Ligthelm R, Ross S, Svendsen AL, Yale JF, SOLVE Study Group.
    Drugs Aging; 2013 Mar; 30(3):167-75. PubMed ID: 23371395
    [Abstract] [Full Text] [Related]

  • 2. [Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].
    Liebl A, Wilhelm B, Kaiser M.
    MMW Fortschr Med; 2012 Dec 17; 154 Suppl 4():102-9. PubMed ID: 23326928
    [Abstract] [Full Text] [Related]

  • 3. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov 17; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 4. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group.
    Diabetes Obes Metab; 2009 Jun 17; 11(6):623-31. PubMed ID: 19515182
    [Abstract] [Full Text] [Related]

  • 5. [Effectiveness and safety of initiation of once-daily insulin detemir in Chinese patients with type 2 diabetes previously treated with different quantities of oral anti-diabetic drugs: subgroup analysis of the Chinese SOLVE™ Study].
    Pan C, Ji L, Lu J, Yang W, Zhou Z, Chinese SOLVE™ Study.
    Zhonghua Nei Ke Za Zhi; 2015 Jul 17; 54(7):612-7. PubMed ID: 26359024
    [Abstract] [Full Text] [Related]

  • 6. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.
    Clin Ther; 2007 Nov 17; 29(11):2374-84. PubMed ID: 18158078
    [Abstract] [Full Text] [Related]

  • 7. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF, Dornhorst A, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2009 Apr 17; 25(4):1029-35. PubMed ID: 19281426
    [Abstract] [Full Text] [Related]

  • 8. PREDICTIVE- a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort.
    Lüddeke HJ, Sreenan S, Aczel S, Maxeiner S, Yenigun M, Kozlovski P, Gydesen H, Dornhorst A, PREDICTIVE Study Group.
    Diabetes Obes Metab; 2007 May 17; 9(3):428-34. PubMed ID: 17391171
    [Abstract] [Full Text] [Related]

  • 9. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
    Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B, PREFER Study Group.
    Diabetes Obes Metab; 2009 Jan 17; 11(1):45-52. PubMed ID: 18643839
    [Abstract] [Full Text] [Related]

  • 10. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU, Plewe G, Busch K.
    J Am Geriatr Soc; 2007 Feb 17; 55(2):182-8. PubMed ID: 17302653
    [Abstract] [Full Text] [Related]

  • 11. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
    Fakhoury W, Lockhart I, Kotchie RW, Aagren M, LeReun C.
    Pharmacology; 2008 Feb 17; 82(2):156-63. PubMed ID: 18679040
    [Abstract] [Full Text] [Related]

  • 12. Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice.
    Khunti K, Damci T, Meneghini L, Pan CY, Yale JF, SOLVE Study Group.
    Diabetes Obes Metab; 2012 Jul 17; 14(7):654-61. PubMed ID: 22443213
    [Abstract] [Full Text] [Related]

  • 13. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R.
    Diabetes Obes Metab; 2006 Jan 17; 8(1):58-66. PubMed ID: 16367883
    [Abstract] [Full Text] [Related]

  • 14. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A, Lüddeke HJ, Koenen C, Meriläinen M, King A, Robinson A, Sreenan S, PREDICTIVE Study Group.
    Diabetes Obes Metab; 2008 Jan 17; 10(1):75-81. PubMed ID: 18034846
    [Abstract] [Full Text] [Related]

  • 15. Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center.
    Cander S, Dizdar OS, Oz Gul O, Guclu M, Unal OK, Tuncel E, Erturk E, Imamoglu S, Ersoy C.
    Prim Care Diabetes; 2014 Oct 17; 8(3):256-64. PubMed ID: 24522170
    [Abstract] [Full Text] [Related]

  • 16. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
    Vora J, Caputo S, Damci T, Orozco-Beltran D, Pan C, Svendsen AL, Sølje KS, Khunti K, SOLVE study group.
    J Clin Pharm Ther; 2014 Apr 17; 39(2):136-43. PubMed ID: 24329524
    [Abstract] [Full Text] [Related]

  • 17. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G.
    Diabetologia; 2008 Mar 17; 51(3):408-16. PubMed ID: 18204830
    [Abstract] [Full Text] [Related]

  • 18. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.
    Khunti K, Caputo S, Damci T, Dzida GJ, Ji Q, Kaiser M, Karnieli E, Liebl A, Ligthelm RJ, Nazeri A, Orozco-Beltran D, Pan C, Ross SA, Svendsen AL, Vora J, Yale JF, Meneghini LF, SOLVE Study Group.
    Diabetes Obes Metab; 2012 Dec 17; 14(12):1129-36. PubMed ID: 22830956
    [Abstract] [Full Text] [Related]

  • 19. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ.
    Diabetes Obes Metab; 2007 May 17; 9(3):418-27. PubMed ID: 17391170
    [Abstract] [Full Text] [Related]

  • 20. Insulin detemir: a review of its use in the management of diabetes mellitus.
    Keating GM.
    Drugs; 2012 Dec 03; 72(17):2255-87. PubMed ID: 23110609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.